Intravitreal anti-VEGF injections linked to increased systemic adverse events in diabetic patients

Although intravitreal anti-VEGF injections are a widely used treatment for diabetic retinopathy (DR), they may be associated with an elevated risk of systemic adverse events, especially in high-risk patient groups, according to a new study published in JAMA Ophthalmology. The study included 1,731,782 patients with type 2 diabetes seen at...